Hormone-refractory prostate cancer: where are we going?
This article addresses the current status of therapeutic options in the management of hormone-refractory prostate cancer (HRPC). Following the publication of two landmark randomised trials, docetaxel chemotherapy is now the standard of care for men with metastatic HRPC. However, the benefit of this treatment is limited. Trials are now focusing on improving the efficacy of docetaxel by combining it with novel biological agents. Several new docetaxel-based combinations are under evaluation and promising results have been found for the combination of docetaxel with angiogenesis inhibitors. Early phase III trial data for atrasentan appear interesting. New cytotoxic agents such as satraplatin and ixabepilone are being investigated in several ongoing studies in order to define their role as second-line treatments of HRPC. Vaccine therapy offers an active immunological approach for combating malignancy in a targeted manner.
Di Lorenzo
Giuseppe
G
Department of Clinical and Molecular Oncology, Federico II University, Naples, Italy. giuseppedilorenzoncol@hotmail.com
Autorino
Riccardo
R
Figg
William D
WD
De Placido
Sabino
S
D000726:Androgen Antagonists / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use; D000077143:Docetaxel; D004351:Drug Resistance; D006801:Humans; D007167:Immunotherapy; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D043823:Taxoids / Q000627:therapeutic use
D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D043823:Taxoids; D000077143:Docetaxel